Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Gastroenterology
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Endoscopy | Research

Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis

Authors: Ken Haruma, Yoshikazu Kinoshita, Takashi Yao, Ryoji Kushima, Junichi Akiyama, Nobuo Aoyama, Tatsuhiro Kanoo, Kouji Miyata, Naomi Kusumoto, Naomi Uemura

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Background

VISION is a randomised, phase 4, open-label, parallel-group, multicentre study conducted in 33 centres in Japan. The aim of this study was to assess the long-term safety of vonoprazan for maintenance treatment of healed erosive oesophagitis versus lansoprazole.

Methods

Patients with endoscopically diagnosed erosive oesophagitis were randomised 2:1 to once-daily vonoprazan 20 mg or lansoprazole 30 mg, for a 4- to 8-week healing phase. Patients with endoscopically confirmed healing entered a 260-week maintenance phase with a once-daily starting dose of vonoprazan 10 mg or lansoprazole 15 mg. Primary endpoint was change in gastric mucosal histopathology.

Results

Of 208 patients (vonoprazan, n = 139; lansoprazole, n = 69) entering the healing phase, 202 entered the maintenance phase (vonoprazan, n = 135; lansoprazole, n = 67). At 3 years, 109 vonoprazan-treated and 58 lansoprazole-treated patients remained on treatment. Histopathological evaluation of gastric mucosa showed that hyperplasia of parietal, foveolar and G cells was more common with vonoprazan than lansoprazole at week 156 of the maintenance phase. There was no marked increase in the occurrence of parietal, foveolar and G cell hyperplasia among patients in the vonoprazan group from week 48 to week 156. Histopathological evaluation of the gastric mucosa also showed no neoplastic changes in either group. No new safety issues were identified.

Conclusions

In this interim analysis of VISION, no new safety concerns were identified in Japanese patients with healed erosive oesophagitis receiving vonoprazan or lansoprazole as maintenance treatment for 3 years. (CT.gov identifier: NCT02679508; JapicCTI-163153; Japan Registry of Clinical Trials: jRCTs031180040).
Appendix
Available only for authorised users
Literature
1.
Hori Y, Imanishi A, Matsukawa J, Tsukimi Y, Nishida H, Arikawa Y, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther. 2010;335(1):231–8.PubMedCrossRef
2.
Shin JM, Inatomi N, Munson K, Strugatsky D, Tokhtaeva E, Vagin O, et al. Characterization of a novel potassium-competitive acid blocker of the gastric H, K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther. 2011;339(2):412–20.PubMedPubMedCentralCrossRef
3.
Sugano K. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Therap Adv Gastroenterol. 2018;11:1756283X17745776.PubMedPubMedCentralCrossRef
4.
Iwakiri K, Sakurai Y, Shiino M, Okamoto H, Kudou K, Nishimura A, et al. A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis. Therap Adv Gastroenterol. 2017;10(6):439–51.PubMedPubMedCentralCrossRef
5.
Mizuno H, Yamada K, Minouchi K, Kamiyamamoto S, Hinoue Y. Efficacy of vonoprazan for 24-week maintenance therapy of patients with healed reflux esophagitis refractory to proton pump inhibitors. Biomed Rep. 2018;8(2):148–55.PubMed
6.
Tanabe T, Hoshino S, Kawami N, Hoshikawa Y, Hanada Y, Takenouchi N, et al. Efficacy of long-term maintenance therapy with 10-mg vonoprazan for proton pump inhibitor-resistant reflux esophagitis. Esophagus. 2019;16(4):377–81.PubMedCrossRef
7.
Ashida K, Sakurai Y, Nishimura A, Kudou K, Hiramatsu N, Umegaki E, et al. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 2015;42(6):685–95.PubMedPubMedCentralCrossRef
8.
Ashida K, Sakurai Y, Hori T, Kudou K, Nishimura A, Hiramatsu N, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016;43(2):240–51.PubMedCrossRef
9.
Ashida K, Iwakiri K, Hiramatsu N, Sakurai Y, Hori T, Kudou K, et al. Maintenance for healed erosive esophagitis: phase III comparison of vonoprazan with lansoprazole. World J Gastroenterol. 2018;24(14):1550–61.PubMedPubMedCentralCrossRef
10.
Xiao Y, Zhang S, Dai N, Fei G, Goh KL, Chun HJ, et al. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. Gut. 2020;69(2):224–30.PubMedCrossRef
11.
Iwakiri K, Kinoshita Y, Habu Y, Oshima T, Manabe N, Fujiwara Y, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol. 2016;51(8):751–67.PubMedCrossRef
12.
Matsukawa J, Hori Y, Nishida H, Kajino M, Inatomi N. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol. 2011;81(9):1145–51.PubMedCrossRef
13.
14.
15.
16.
Mastracci L, Rindi G, Grillo F, Solcia E, Campora M, Fassan M, et al. Neuroendocrine neoplasms of the esophagus and stomach. Pathologica. 2021;113(1):5–11.PubMedPubMedCentralCrossRef
17.
Sumiyoshi H, Yasui W, Ochiai A, Tahara E. Effects of gastrin on tumor growth and cyclic nucleotide metabolism in xenotransplantable human gastric and colonic carcinomas in nude mice. Cancer Res. 1984;44(10):4276–80.PubMed
18.
Takhar AS, Eremin O, Watson SA. The role of gastrin in colorectal carcinogenesis. Surgeon. 2004;2(5):251–7.PubMedCrossRef
19.
Walsh JH. Role of gastrin as a trophic hormone. Digestion. 1990;47(Suppl 1):11–6; discussion 49-52.PubMedCrossRef
20.
Koh TJ, Chen D. Gastrin as a growth factor in the gastrointestinal tract. Regul Pept. 2000;93(1–3):37–44.PubMedCrossRef
21.
Baldwin GS. The role of gastrin and cholecystokinin in normal and neoplastic gastrointestinal growth. J Gastroenterol Hepatol. 1995;10(2):215–32.PubMedCrossRef
22.
Chen WC, Warner RRP, Harpaz N, Zhu H, Roayaie S, Kim MK. Gastric neuroendocrine tumor and duodenal gastrinoma with chronic autoimmune atrophic gastritis. Pancreas. 2019;48(1):131–4.PubMedCrossRef
23.
Ito M, Tanaka S, Maeda M, Takamura A, Tatsugami M, Wada Y, et al. Role of the gastrin-gastrin receptor system in the expansive growth of human gastric neoplasms. Digestion. 2008;78(2–3):163–70.PubMedCrossRef
24.
Kinoshita Y, Ishihara S. Mechanism of gastric mucosal proliferation induced by gastrin. J Gastroenterol Hepatol. 2000;15(Suppl):D7-11.PubMedCrossRef
25.
García Rodríguez LA, Lagergren J, Lindblad M. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut. 2006;55(11):1538–44.PubMedCrossRef
26.
Tamim H, Duranceau A, Chen LQ, Lelorier J. Association between use of acid-suppressive drugs and risk of gastric cancer. A nested case-control study. Drug Saf. 2008;31(8):675–84.PubMedCrossRef
27.
Poulsen AH, Christensen S, McLaughlin JK, Thomsen RW, Sørensen HT, Olsen JH, et al. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study. Br J Cancer. 2009;100(9):1503–7.PubMedPubMedCentralCrossRef
28.
Brusselaers N, Wahlin K, Engstrand L, Lagergren J. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open. 2017;7(10):e017739.PubMedPubMedCentralCrossRef
29.
Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut. 2018;67(1):28–35.PubMedCrossRef
30.
Niikura R, Hayakawa Y, Hirata Y, Yamada A, Fujishiro M, Koike K. Long-term proton pump inhibitor use is a risk factor of gastric cancer after treatment for Helicobacter pylori: a retrospective cohort analysis. Gut. 2018;67(10):1908–10.PubMedCrossRef
31.
Lai SW, Lai HC, Lin CL, Liao KF. Proton pump inhibitors and risk of gastric cancer in a case-control study. Gut. 2019;68(4):765–7.PubMedCrossRef
32.
Peng YC, Huang LR, Lin CL, Hsu WY, Chang CS, Yeh HZ, et al. Association between proton pump inhibitors use and risk of gastric cancer in patients with GERD. Gut. 2019;68(2):374–6.PubMedCrossRef
33.
Cheung KS, Leung WK. Long-term use of proton-pump inhibitors and risk of gastric cancer: a review of the current evidence. Therap Adv Gastroenterol. 2019;12:1756284819834511.PubMedPubMedCentralCrossRef
34.
Haruma K, Yoshihara M, Sumii K, Tari A, Watanabe C, Kodoi A, et al. Gastric acid secretion, serum pepsinogen I, and serum gastrin in Japanese with gastric hyperplastic polyps or polypoid-type early gastric carcinoma. Scand J Gastroenterol. 1993;28(7):633–7.PubMedCrossRef
35.
Martin FC, Chenevix-Trench G, Yeomans ND. Systematic review with meta-analysis: fundic gland polyps and proton pump inhibitors. Aliment Pharmacol Ther. 2016;44(9):915–25.PubMedCrossRef
36.
Hongo M, Fujimoto K. Incidence and risk factor of fundic gland polyp and hyperplastic polyp in long-term proton pump inhibitor therapy: a prospective study in Japan. J Gastroenterol. 2010;45(6):618–24.PubMedCrossRef
37.
Takahari K, Haruma K, Ohtani H, Kiyoto S, Watanabe A, Kamada T, et al. Proton pump inhibitor induction of gastric cobblestone-like lesions in the stomach. Intern Med. 2017;56(20):2699–703.PubMedPubMedCentralCrossRef
38.
Hasegawa R, Yao K, Ihara S, Miyaoka M, Kanemitsu T, Chuman K, et al. Magnified endoscopic findings of multiple white flat lesions: a new subtype of gastric hyperplastic polyps in the stomach. Clin Endosc. 2018;51(6):558–62.PubMedPubMedCentralCrossRef
39.
Hatano Y, Haruma K, Ayaki M, Kamada T, Ohtani H, Murao T, et al. Black spot, a novel gastric finding potentially induced by proton pump inhibitors. Intern Med. 2016;55(21):3079–84.PubMedPubMedCentralCrossRef
40.
Uemura N, Kinoshita Y, Haruma K, Yao T, Kushima R, Kanoo T. Rationale and design of the VISION study: a randomized, open-label study to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis. Clin Exp Gastroenterol. 2018;11:51–6.PubMedPubMedCentralCrossRef
41.
Iwai K, Yao T, Nakamura S, Matsumoto T, Nishiyama K, Iida M, et al. Multiple gastric carcinoids and endocrine cell micronests in type A gastritis: nuclear morphometric and immunohistochemical analysis. Oncol Rep. 2005;13(3):397–404.PubMed
42.
Mizokami Y, Oda K, Funao N, Nishimura A, Soen S, Kawai T, et al. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut. 2018;67(6):1042–51.PubMedCrossRef
43.
Kawai T, Oda K, Funao N, Nishimura A, Matsumoto Y, Mizokami Y, et al. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut. 2018;67(6):1033–41.PubMedCrossRef
44.
Vanoli A, La Rosa S, Luinetti O, Klersy C, Manca R, Alvisi C, et al. Histologic changes in type A chronic atrophic gastritis indicating increased risk of neuroendocrine tumor development: the predictive role of dysplastic and severely hyperplastic enterochromaffin-like cell lesions. Hum Pathol. 2013;44(9):1827–37.PubMedCrossRef
45.
Haruma K, Kato M, Inoue K, Murakami K, Kamada T. Kyoto classification of gastritis. 1st ed. Tokyo: Nihon Medical Center; 2017.
46.
Saito M, Koike T, Abe Y, Nakagawa K, Kanno T, Jin X, et al. The development of foveolar-type gastric adenocarcinoma during maintenance therapy of vonoprazan for reflux esophagitis. Intern Med. 2021;60(3):391–6.PubMedCrossRef
47.
Campana D, Nori F, Piscitelli L, Morselli-Labate AM, Pezzilli R, Corinaldesi R, et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol. 2007;25(15):1967–73.PubMedCrossRef
48.
Nielsen HO, Jensen KB, Christiansen LA. The antral gastrin-producing cells in duodenal ulcer patients. A density study before and during treatment with cimetidine. Acta Pathol Microbiol Scand A. 1980;88(6):383–6.PubMed
49.
Pashankar DS, Israel DM, Jevon GP, Buchan AM. Effect of long-term omeprazole treatment on antral G and D cells in children. J Pediatr Gastroenterol Nutr. 2001;33(5):537–42.PubMedCrossRef
50.
Sano J, Miki K, Ichinose M, Kimura M, Kurokawa K, Aida T, et al. In situ localization of pepsinogens I and II mRNA in human gastric mucosa. Acta Pathol Jpn. 1989;39(12):765–71.PubMed
51.
Qian JM, Rowley WH, Jensen RT. Gastrin and CCK activate phospholipase C and stimulate pepsinogen release by interacting with two distinct receptors. Am J Physiol. 1993;264(4 Pt 1):G718–27.PubMed
52.
Cherner JA, Sutliff VE, Grybowski DM, Jensen RT, Gardner JD. Functionally distinct receptors for cholecystokinin and gastrin on dispersed chief cells from guinea pig stomach. Am J Physiol. 1988;254(2 Pt 1):G151–5.PubMed
53.
Nishino K, Kawanaka M, Suehiro M, Yoshioka N, Nakamura J, Urata N, et al. Gastric hyperplastic polyps after argon plasma coagulation for gastric antral vascular ectasia in patients with liver cirrhosis: a case suggesting the “gastrin link theory.” Intern Med. 2021;60(7):1019–25.PubMedCrossRef
54.
Kuipers EJ, Lee A, Klinkenberg-Knol EC, Meuwissen SG. Review article: the development of atrophic gastritis—Helicobacter pylori and the effects of acid suppressive therapy. Aliment Pharmacol Ther. 1995;9(4):331–40.PubMedCrossRef
55.
Klinkenberg-Knol EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology. 2000;118(4):661–9.PubMedCrossRef
56.
Nasser SC, Slim M, Nassif JG, Nasser SM. Influence of proton pump inhibitors on gastritis diagnosis and pathologic gastric changes. World J Gastroenterol. 2015;21(15):4599–606.PubMedPubMedCentralCrossRef
57.
Marusic M, Babic Z, Nesanovic M, Lucijanic-Mlinac M, Stajcar V. Influence of various proton pump inhibitors on intestinal metaplasia in noneradicated Helicobacter pylori patients. World J Gastroenterol. 2005;11(15):2334–6.PubMedPubMedCentralCrossRef
58.
Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Havu N, Festen HP, Liedman B, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med. 1996;334(16):1018–22.PubMedCrossRef
59.
Kuipers EJ, Uyterlinde AM, Peña AS, Hazenberg HJ, Bloemena E, Lindeman J, et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol. 1995;90(9):1401–6.PubMed
60.
Lundell L, Miettinen P, Myrvold HE, Pedersen SA, Thor K, Andersson A, et al. Lack of effect of acid suppression therapy on gastric atrophy. Nordic GERD Study Group. Gastroenterology. 1999;117(2):319–26.PubMedCrossRef
61.
Song H, Zhu J, Lu D. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions. Cochrane Database Syst Rev. 2014;12:Cd010623.
62.
Sumi N, Haruma K, Kamada T, Suehiro M, Manabe N, Akiyama T, et al. Inflammatory cell numbers in the stomach of Japanese subjects with endoscopically normal mucosa without Helicobacter pylori infection. Dig Dis. 2021;39(6):598–605.PubMedCrossRef
63.
Matsuhisa T, Arakawa T, Watanabe T, Tokutomi T, Sakurai K, Okamura S, et al. Relation between bile acid reflux into the stomach and the risk of atrophic gastritis and intestinal metaplasia: a multicenter study of 2283 cases. Dig Endosc. 2013;25(5):519–25.PubMedCrossRef
64.
Nakamura M, Haruma K, Kamada T, Mihara M, Yoshihara M, Sumioka M, et al. Cigarette smoking promotes atrophic gastritis in Helicobacter pylori-positive subjects. Dig Dis Sci. 2002;47(3):675–81.PubMedCrossRef
65.
Haber MM, Hunt B, Freston JW, Peura DA, Kovacs TO, Atkinson S, et al. Changes of gastric histology in patients with erosive oesophagitis receiving long-term lansoprazole maintenance therapy. Aliment Pharmacol Ther. 2010;32(1):83–96.PubMedCrossRef
66.
Tanigawa T, Watanabe T, Higuchi K, Machida H, Okazaki H, Yamagami H, et al. Lansoprazole, a proton pump inhibitor, suppresses production of tumor necrosis factor-alpha and interleukin-1beta induced by lipopolysaccharide and Helicobacter pylori bacterial components in human monocytic cells via inhibition of activation of nuclear factor-kappaB and extracellular signal-regulated kinase. J Clin Biochem Nutr. 2009;45(1):86–92.PubMedPubMedCentralCrossRef
67.
Haruma K, Hamada H, Mihara M, Kamada T, Yoshihara M, Sumii K, et al. Negative association between Helicobacter pylori infection and reflux esophagitis in older patients: case-control study in Japan. Helicobacter. 2000;5(1):24–9.PubMedCrossRef
68.
Shibagaki K, Fukuyama C, Mikami H, Izumi D, Yamashita N, Mishiro T, et al. Gastric foveolar-type adenomas endoscopically showing a raspberry-like appearance in the Helicobacter pylori-uninfected stomach. Endosc Int Open. 2019;7(6):E784–91.PubMedPubMedCentralCrossRef
69.
Shibagaki K, Mishiro T, Fukuyama C, Takahashi Y, Itawaki A, Nonomura S, et al. Sporadic foveolar-type gastric adenoma with a raspberry-like appearance in Helicobacter pylori-naïve patients. Virchows Arch. 2021;479(4):687–95.PubMedCrossRef
Metadata
Title
Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis
Authors
Ken Haruma
Yoshikazu Kinoshita
Takashi Yao
Ryoji Kushima
Junichi Akiyama
Nobuo Aoyama
Tatsuhiro Kanoo
Kouji Miyata
Naomi Kusumoto
Naomi Uemura
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-02772-w

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue

Research

The impact of intrahepatic cholestasis on pregnancy outcomes: a retrospective cohort study

Correction

Correction: Assessing clinical trial failure risk factors and reasons in gastric cancer

Research

Glepaglutide, a novel glucagon-like peptide-2 agonist, has anti-inflammatory and mucosal regenerative effects in an experimental model of inflammatory bowel disease in rats

Research

Gastroesophageal reflux disease symptoms and associated factors among university students in Amhara region, Ethiopia, 2021: a cross-sectional study

Research article

Systematic review of cholangiocarcinoma in Africa: epidemiology, management, and clinical outcomes

Research

Cirrhosis in intrahepatic cholangiocarcinoma: prognostic importance and impact on survival
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits